| CPC A61K 9/7053 (2013.01) [A61K 31/13 (2013.01); A61K 31/27 (2013.01); A61K 31/381 (2013.01); A61K 31/403 (2013.01); A61K 31/407 (2013.01); A61K 31/4422 (2013.01); A61K 31/573 (2013.01)] | 2 Claims |
|
1. A patch comprising an adhesive layer on a backing, wherein:
the adhesive layer contains an adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate,
the skin irritant drug is selected from the group consisting of asenapine, rivastigmine, rotigotine, memantine, ropinirole, and a pharmaceutically acceptable salt thereof,
the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer, and
wherein when the skin irritant drug is asenapine, the adhesive layer comprises a mass ratio of asenapine or a pharmaceutically acceptable salt thereof and diflucortolone valerate of 12.5:1 to 27778:1;
wherein when skin irritant drug is rivastigmine, the adhesive layer comprises a mass ratio of rivastigmine or a pharmaceutically acceptable salt thereof and diflucortolone valerate of 75:1 to 33333:1;
wherein when the skin irritant drug is rotigotine, the adhesive layer comprises a mass ratio of rotigotine or a pharmaceutically acceptable salt thereof and diflucortolone valerate is 62.5:1 to 20000:1;
wherein when the skin irritant drug is memantine, the adhesive layer comprises a mass ratio of memantine or a pharmaceutically acceptable salt thereof and diflucortolone valerate is 1.25:1 to 55556:1; and
wherein when the skin irritant drug is ropinirole, the adhesive layer comprises a mass ratio of ropinirole or a pharmaceutically acceptable salt thereof and diflucortolone valerate is 6.25:1 to 55556:1.
|